We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

SMC:NYSESummit Midstream Corporation Analysis

Data as of 2026-09-01 - not real-time

$34.72

Latest Price

6/10Risk

Risk Level: Medium

Executive Summary

At $34.72, Summit Midstream Corporation shows a bullish moving-average alignment, with shorter averages sitting above longer ones. The last 30 days have gained 13.4%. RSI sits at 64.5, which reads as approaching overbought, and MACD momentum is bearish. Recent trading has carved out support near $29.97 and resistance around $36.47.
The company is not currently profitable on a trailing basis, so earnings multiples offer no valuation support. The average analyst target implies 35.4% above today's level. Revenue is growing at 10.6% on a -3.5% profit margin.
On a 1-10 scale the risk profile lands at 6 — elevated. With 30-day volatility of 33.5%, a beta of 0.33 and a maximum drawdown of 18.3%, position sizing matters here. The wider market backdrop reads extreme greed at 94 on the fear-greed composite.
Across every horizon the signals point the same way: hold, at a conviction of 2 out of 10.

Top Market Events

Summit Midstream SMC   that its Board continued to suspend cash dividends payable on the common stock for the period...Updated Jul 30, 2026 0 HOUSTON, July 30, 2026 /PRNewswire/ -- Summit Midstream Corporation NYSE: SMC "Summit", "SMC" or...EBITDA rose 12% in Rockies and Mid-Con; management eyes 3.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 3/10

Key Factors

  • Short-term moving averages stacked above long-term ones
  • Trading above the 200-day average of 29.41
  • MACD momentum is negative

Medium Term

1–3 years
Neutral
Model confidence: 3/10

Key Factors

  • Short-term moving averages stacked above long-term ones
  • Trading above the 200-day average of 29.41
  • Analyst targets imply +35.4% versus the current price

Long Term

> 3 years
Neutral
Model confidence: 2/10

Key Factors

  • Negative profit margin of -3.5%
  • Analyst targets imply +35.4% versus the current price
  • Negative return on equity of -2.9%

Key Metrics & Analysis

Financial Health

Revenue Growth10.60%
Profit Margin-3.55%
P/E Ratio-14.8
ROE-2.92%
ROA2.37%
Debt/Equity134.91
P/B Ratio0.9
Op. Cash Flow$131.2M
Free Cash Flow$-3568875
Industry P/E21.7

Technical Analysis

TrendBullish
RSI64.5
Support$29.97
Resistance$36.47
MA 20$33.71
MA 50$31.50
MA 200$29.41
MACDBearish
VolumeDecreasing
Fear & Greed Index93.66

Valuation

Fair Value$43.92
Target Price$47.00
Upside/Downside35.37%
GradeUndervalued
TypeBlend

Risk Assessment

Beta0.33
Volatility33.51%
Sector RiskHigh
Reg. RiskHigh
Geo RiskLow
Currency RiskLow
Liquidity RiskMedium

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.